In a win for drug company Allergan Inc., a federal judge in North Carolina Jan. 24 found that generic companies’ abbreviated new drug applications to make generic versions of the eyelash treatment Latisse (bimatoprost ophthalmic solution 0.03 percent) infringed two patents covering the product (Allergan Inc. v. Apotex Inc., M.D.N.C., 1:10-cv-00681-CCE-LPA, 1/24/13).
Accordingly, Judge Catherine C. Eagles of the U.S. District Court for the Middle District of North Carolina blocked the generic companies—Apotex Inc., Sandoz Inc., and Hi-Tech Pharmacal Co.—from commercializing their generic products until the Latisse patents expire.
The patents in question, U.S. Patent Nos. 7,388,029 ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.